Paul  Thomas net worth and biography

Paul Thomas Biography and Net Worth

Director of AxoGen

Mr. Thomas has served as a member of our Board of Directors since September 2020. Mr. Thomas has more than 30 years of experience in the medtech industry and currently serves as the CEO and Co-Founder of Prominex, Inc. Mr. Thomas also served as the CEO of Roka Bioscience from 2009 to 2017. Prior to that, Mr. Thomas served as Chairman and CEO of LifeCell Corporation from 1998 until it was acquired by KCI in 2008 in a transaction valued at $1.8 billion. He also held various senior positions, including President of the Pharmaceutical Products Division, during his tenure of 15 years with Ohmeda, Inc. Mr. Thomas received his Master of Business Administration degree from Columbia University Graduate School of Business and completed his post graduate studies in Chemistry at the University of Georgia Graduate School of Arts and Science. He received his Bachelor of Science degree in Chemistry from St. Michael’s College. Mr. Thomas’ qualifications to serve on our Board of Directors include his extensive executive leadership and financial experience, particularly in connection with rapid growth technology businesses, and his experience as a director of publicly traded companies.

What is Paul Thomas' net worth?

The estimated net worth of Paul Thomas is at least $473.75 thousand as of December 9th, 2025. Thomas owns 13,528 shares of AxoGen stock worth more than $473,751 as of February 2nd. This net worth estimate does not reflect any other investments that Thomas may own. Learn More about Paul Thomas' net worth.

How do I contact Paul Thomas?

The corporate mailing address for Thomas and other AxoGen executives is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. AxoGen can also be reached via phone at (386) 462-6800 and via email at [email protected]. Learn More on Paul Thomas' contact information.

Has Paul Thomas been buying or selling shares of AxoGen?

Paul Thomas has not been actively trading shares of AxoGen over the course of the past ninety days. Most recently, Paul Thomas sold 21,399 shares of the business's stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $29.61, for a transaction totalling $633,624.39. Following the completion of the sale, the director now directly owns 13,528 shares of the company's stock, valued at $400,564.08. Learn More on Paul Thomas' trading history.

Who are AxoGen's active insiders?

AxoGen's insider roster includes Marc Began (EVP), P Burke (Director), Michael Dale (CEO), Erick Devinney (Insider), Michael Donovan (VP), Gregory Freitag (Director), Lindsey Hartley (CFO), John Johnson (Director), Peter Mariani (CFO), Maria Martinez (Insider), Guido Neels (Director), Paul Thomas (Director), Joseph Tyndall (Director), Kathy Weiler (Director), Amy Wendell (Director), and Karen Zaderej (CEO). Learn More on AxoGen's active insiders.

Are insiders buying or selling shares of AxoGen?

In the last twelve months, insiders at the medical equipment provider sold shares 27 times. They sold a total of 475,453 shares worth more than $12,603,234.48. The most recent insider tranaction occured on December, 16th when Director Amy Mcbride Wendell sold 43,684 shares worth more than $1,280,378.04. Insiders at AxoGen own 2.8% of the company. Learn More about insider trades at AxoGen.

Information on this page was last updated on 12/16/2025.

Paul Thomas Insider Trading History at AxoGen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/9/2025Sell21,399$29.61$633,624.3913,528View SEC Filing Icon  
See Full Table

Paul Thomas Buying and Selling Activity at AxoGen

This chart shows Paul Thomas's buying and selling at AxoGen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AxoGen Company Overview

AxoGen logo
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
Read More

Today's Range

Now: $35.81
Low: $34.21
High: $35.74

50 Day Range

MA: $31.65
Low: $27.69
High: $35.02

2 Week Range

Now: $35.81
Low: $9.22
High: $36.00

Volume

209,925 shs

Average Volume

1,024,888 shs

Market Capitalization

$1.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1